NCT03575013View on ClinicalTrials.gov

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

December 15, 2021

Study Completion Date

February 23, 2026

Conditions
Urothelial Carcinoma
Interventions
DRUG

Avelumab

Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody

DRUG

Docetaxel

Docetaxel is a antineoplastic agent belonging to the taxoid family

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

University of Iowa

OTHER

lead

Yousef Zakharia

OTHER